Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
Atossa Therapeutics, a clinical stage biopharmaceutical company focused on developing innovative medicines for breast cancer and other areas of significant unmet medical need in oncology, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. Michael Parks, Vice President of Investor and Public Relations at Atossa, will engage in a virtual fireside chat on Wednesday, October 16, 2024, at 12:00 p.m. EDT.
The company, traded on Nasdaq under the ticker ATOS, invites interested parties to register and access the live webcast of the conference through a provided link. This event presents an opportunity for investors and stakeholders to gain insights into Atossa's current developments and future prospects in the oncology field.
Atossa Therapeutics, un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di farmaci innovativi per il cancro al seno e altre aree con significativi bisogni medici insoddisfatti in oncologia, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. Michael Parks, Vicepresidente delle Relazioni con gli Investitori e Pubbliche Relazioni di Atossa, parteciperà a un chat informale virtuale mercoledì, 16 ottobre 2024, alle 12:00 EDT.
L'azienda, quotata su Nasdaq con il ticker ATOS, invita le parti interessate a registrarsi e accedere alla diretta del convegno tramite un link fornito. Questo evento offre un'opportunità per investitori e stakeholder di approfondire gli sviluppi attuali e le prospettive future di Atossa nel campo dell'oncologia.
Atossa Therapeutics, una empresa biofarmacéutica en etapa clínica centrada en desarrollar medicamentos innovadores para el cáncer de mama y otras áreas de gran necesidad médica no satisfecha en oncología, ha anunciado su participación en el 2024 Maxim Healthcare Virtual Summit. Michael Parks, Vicepresidente de Relaciones con Inversores y Relaciones Públicas en Atossa, participará en un chat informal virtual el miércoles, 16 de octubre de 2024, a las 12:00 p.m. EDT.
La empresa, que cotiza en Nasdaq bajo el ticker ATOS, invita a las partes interesadas a registrarse y acceder a la transmisión en vivo de la conferencia a través de un enlace proporcionado. Este evento ofrece una oportunidad para que inversores y partes interesadas obtengan información sobre los desarrollos actuales de Atossa y sus perspectivas futuras en el campo de la oncología.
Atossa Therapeutics는 유방암 및 종양학에서의 중요한 미충족 의료 요구가 있는 다른 분야를 위해 혁신적인 의약품 개발에 집중하는 임상 단계의 생명공학 회사입니다. 이 회사는 2024 Maxim Healthcare Virtual Summit에 참가한다고 발표했습니다. Michael Parks님은 Atossa의 투자자 및 공공 관계 부사장으로서 2024년 10월 16일 수요일, 동부 표준시 기준 오후 12시에 가상 대담에 참여할 예정입니다.
회사 주식은 Nasdaq에서 ATOS라는 티커로 거래되며, 관심 있는 당사자들은 제공된 링크를 통해 컨퍼런스의 생중계를 등록하고 접속하기를 초대합니다. 이 행사에서는 투자자와 이해관계자들이 Atossa의 현재 개발 및 종양학 분야에서의 미래 전망에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Atossa Therapeutics, une entreprise biopharmaceutique en phase clinique axée sur le développement de médicaments innovants pour le cancer du sein et d'autres domaines présentant un besoin médical non satisfait important en oncologie, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. Michael Parks, Vice-président des Relations avec les Investisseurs et des Relations Publiques chez Atossa, participera à un chat informel virtuel le mercredi 16 octobre 2024, à 12h00 EDT.
L'entreprise, cotée sur le Nasdaq sous le ticker ATOS, invite les parties intéressées à s'inscrire et à accéder à la diffusion en direct de la conférence via un lien fourni. Cet événement offre une occasion aux investisseurs et aux parties prenantes d'obtenir des informations sur les développements actuels d'Atossa et ses perspectives futures dans le domaine de l'oncologie.
Atossa Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Medikamente für Brustkrebs und andere Bereiche mit erheblichen unerfüllten medizinischen Bedürfnissen in der Onkologie konzentriert, hat seine Teilnahme am 2024 Maxim Healthcare Virtual Summit angekündigt. Michael Parks, Vizepräsident für Investor- und Öffentlichkeitsarbeit bei Atossa, wird am Mittwoch, den 16. Oktober 2024, um 12:00 Uhr EDT an einem virtuellen Gespräch teilnehmen.
Das Unternehmen, das unter dem Ticker ATOS an der Nasdaq gehandelt wird, lädt interessierte Parteien ein, sich anzumelden und über einen bereitgestellten Link auf die Live-Übertragung der Konferenz zuzugreifen. Diese Veranstaltung bietet Investoren und Stakeholdern die Möglichkeit, Einblicke in die aktuellen Entwicklungen von Atossa und die zukünftigen Perspektiven im Bereich der Onkologie zu gewinnen.
- None.
- None.
SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that Michael Parks, Vice President, Investor and Public Relations, will participate in a virtual fireside chat on Wednesday, October 16, 2024 at 12:00 p.m. EDT at the 2024 Maxim Healthcare Virtual Summit. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Interested parties can register and access the live webcast for the conference here.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.
Contact:
Michael Parks
Vice President, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
FAQ
When is Atossa Therapeutics (ATOS) presenting at the 2024 Maxim Healthcare Virtual Summit?
Who will be representing Atossa Therapeutics (ATOS) at the 2024 Maxim Healthcare Virtual Summit?
What is the main focus of Atossa Therapeutics (ATOS) in drug development?
How can interested parties access the Atossa Therapeutics (ATOS) presentation at the 2024 Maxim Healthcare Virtual Summit?
